Stock Evaluator: Supernus Pharmaceuticals, Inc. (SUPN)

Supernus Pharmaceuticals, Inc. SUPN

$44.63 -0.98 -2.15%

July 31, 2026 4:00:00 PM EST Volume: 572,074

After Hours: $120.37 0.15 | 0.12% November 10, 2021 7:59 PM EST Volume: 72,713

USD NASD | DELAYED PRICE

SECTOR	INDUSTRY
Health Care	Pharmaceuticals

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:

COMPANY SUMMARY

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.

Commentary & Analysis

Comparison

Which Is a Better Investment, Supernus Pharmaceuticals, Inc. or Trulieve Cannabis Corp. Stock?

Learn more about whether Supernus Pharmaceuticals, Inc. or Trulieve Cannabis Corp. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Michael Rose

Price

Why Supernus Pharmaceuticals, Inc.’s (SUPN) Stock Is Up 6.69%

As of Wednesday, May 06, Supernus Pharmaceuticals, Inc.’s SUPN share price has surged by 6.69%, which has investors questioning if this is right time to sell.

Rosalio Madrigal

Earnings

What You Need to Know About Supernus Pharmaceuticals, Inc.'s Q2 Earnings

Supernus Pharmaceuticals, Inc.'s fiscal Q2 earnings report was released on Tuesday, May 05. Let's dive in to see if (SUPN) missed or beat analyst's expectations.

Michael Rose

Price

Why Supernus Pharmaceuticals, Inc.’s (SUPN) Stock Is Up 5.47%

As of Friday, April 17, Supernus Pharmaceuticals, Inc.’s SUPN share price has surged by 5.47%, which has investors questioning if this is right time to sell.

Jenna Brashear

Comparison

Which Is a Better Investment, Crinetics Pharmaceuticals, Inc. or Supernus Pharmaceuticals, Inc. Stock?

Learn more about whether Crinetics Pharmaceuticals, Inc. or Supernus Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Omar Beirat

Financial Summary

Share Statistics	SUPN	Industry Median	Percentile (All Stocks)
Market Cap (Mil)	$2,590.3	$579.1	57%
Shares Out (Mil)	57.6	43.0	51%
Institutional Ownership	95.6%	84.3%	68%
Float (Mil)	52.1	46.8	48%
Beta	0.54	0.62	30%
Avg Daily Volume (000s)	511	285	59%
Price Change (52-week)	33.0%	63.8%	71%

Growth	SUPN	Industry Median	Percentile (All Stocks)
Sales (5yr)	6.7%	6.7%	44%
Net Income (5yr)	(18.2%)	(1.4%)	22%
EPS (5yr)	(18.0%)	14.9%	15
Dividends (5yr)	0.0%	0.0%	0%
Cash Flow (5yr)	(12.1%)	(14.9%)	57%

Estimates	Qtrly	Current Fiscal Year	Next Fiscal Year
# of Estimates	3	3	3
Current EPS	$0.510	$2.487	$4.343
Month Ago EPS	$0.455	$2.487	$4.343
# Rev Up	0	1	1
# Rev Down	1	0	0
Three Months Ago EPS	$0.545	$2.340	$4.220
Year/Year Chg	(1,375%)	(464.1%)	(962.4%)

Financials	SUPN	Industry Median	Percentile (All Stocks)
Sales (TTM) (Mil)	$777	$272	47%
Net Income (TTM) (Mil)	($29)	($11)	21%
EPS (TTM)	($0.510)	($0.500)	27%
Operating Cash Flow (TTM) (Mil)	$83	($6)	51%
Net Cash Flow (TTM) (Mil)	$71	$4	74%
Long-Term Debt (Q1) (Mil)	$30	$7	35%
Enterprise Value (Q1) (Mil)	$2,435	$522	52%

Valuation	SUPN	Industry Median	Percentile (All Stocks)
P/B	2.41	2.73	58%
P/E	na	20.5	na
Dividend Yield	0.0%	0.0%	0%
PEG (5yr hist)	na	1.2	na

Ratios	SUPN	Industry Median	Percentile (All Stocks)
Gross Margin	74.1%	65.9%	85%
Net Margin	(3.7%)	0.7%	26%
ROA	(2.0%)	(24.6%)	34%
ROE	(2.8%)	(19.7%)	33%
Liabilities to Assets	28.2%	35.5%	20%
F-Score	3	3	19%

Supernus Pharmaceuticals, Inc. did not pass any screens on 7/31/2026.

Stock Evaluator: Supernus Pharmaceuticals, Inc. (SUPN) + Follow This Stock

Supernus Pharmaceuticals, Inc. (SUPN )